BACKGROUND AND OBJECTIVE: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans. METHODS: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albuminin ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds. A six-point scale was used to assess discomfort. RESULTS: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. CONCLUSION: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.
RCT Entities:
BACKGROUND AND OBJECTIVE: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of humanalbumin delivered subcutaneously to healthy humans. METHODS: We compared the tolerability of neutral versus alkaline (pH 10) formulations of humanalbumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds. A six-point scale was used to assess discomfort. RESULTS: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. CONCLUSION: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.
Authors: Miguel A Goenaga; Manuel Millet; Eloy Sánchez; Carmen Garde; José A Carrera; Edurne Arzellus Journal: Ann Pharmacother Date: 2004-08-31 Impact factor: 3.154
Authors: W Kenneth Ward; Ryan G Massoud; Cory J Szybala; Julia M Engle; Joseph El Youssef; Julie M Carroll; Charles T Roberts; Richard D DiMarchi Journal: J Diabetes Sci Technol Date: 2010-11-01
Authors: Firas H El-Khatib; Steven J Russell; David M Nathan; Robert G Sutherlin; Edward R Damiano Journal: Sci Transl Med Date: 2010-04-14 Impact factor: 17.956
Authors: Jessica R Castle; Julia M Engle; Joseph El Youssef; Ryan G Massoud; Kevin C J Yuen; Ryland Kagan; W Kenneth Ward Journal: Diabetes Care Date: 2010-03-23 Impact factor: 17.152
Authors: Melanie A Jackson; Nicholas Caputo; Jessica R Castle; Larry L David; Charles T Roberts; W Kenneth Ward Journal: Curr Diab Rep Date: 2012-12 Impact factor: 4.810
Authors: Nicholas Caputo; Jessica R Castle; Colin P Bergstrom; Julie M Carroll; Parkash A Bakhtiani; Melanie A Jackson; Charles T Roberts; Larry L David; W Kenneth Ward Journal: Peptides Date: 2013-05-04 Impact factor: 3.750
Authors: Nicholas Caputo; Melanie A Jackson; Jessica R Castle; Joseph El Youssef; Parkash A Bakhtiani; Colin P Bergstrom; Julie M Carroll; Matthew E Breen; Gerald L Leonard; Larry L David; Charles T Roberts; W Kenneth Ward Journal: Diabetes Technol Ther Date: 2014-06-26 Impact factor: 6.118